WO1992022325A1 - Vaccin et methode de traitement des protozoaires flagelles parasites du sang - Google Patents
Vaccin et methode de traitement des protozoaires flagelles parasites du sang Download PDFInfo
- Publication number
- WO1992022325A1 WO1992022325A1 PCT/US1992/004931 US9204931W WO9222325A1 WO 1992022325 A1 WO1992022325 A1 WO 1992022325A1 US 9204931 W US9204931 W US 9204931W WO 9222325 A1 WO9222325 A1 WO 9222325A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunoprotection
- vaccine
- brucei
- trypanosoma
- trvpanosoma
- Prior art date
Links
- 230000003071 parasitic effect Effects 0.000 title claims abstract description 5
- 229960005486 vaccine Drugs 0.000 title claims description 17
- 238000000034 method Methods 0.000 title claims description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 28
- 108091007433 antigens Proteins 0.000 claims abstract description 28
- 241001442397 Trypanosoma brucei rhodesiense Species 0.000 claims abstract description 9
- 241000894007 species Species 0.000 claims abstract description 7
- 241000222722 Leishmania <genus> Species 0.000 claims abstract description 6
- 241000223109 Trypanosoma cruzi Species 0.000 claims abstract description 5
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 206010037075 Protozoal infections Diseases 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 241000222734 Leishmania mexicana Species 0.000 claims description 3
- 241000223104 Trypanosoma Species 0.000 claims description 3
- 229940037003 alum Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 description 25
- 244000045947 parasite Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000223105 Trypanosoma brucei Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000224557 Trypanosoma brucei brucei Species 0.000 description 2
- 241000223099 Trypanosoma vivax Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- XZNXVSDNACTASG-RZNNTOFGSA-M sodium;3,5-diacetamido-2,4,6-triiodobenzoate;3,5-diacetamido-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XZNXVSDNACTASG-RZNNTOFGSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000223095 Trypanosoma evansi Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000028172 protozoa infectious disease Diseases 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Nouvelle protéine antigène initiallement dérivée de Trypanosoma brucei rhodesiense, pouvant être utilisée pour obtenir une protection immunitaire contre tous les Trypanosomes africains, Trypanosoma cruzi (sous-genre), toutes les espèces de Leishmania (genre distinct), et d'autres protozoaires flagellés parasites du sang.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71446491A | 1991-06-13 | 1991-06-13 | |
| US714,464 | 1991-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1992022325A1 true WO1992022325A1 (fr) | 1992-12-23 |
Family
ID=24870150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1992/004931 WO1992022325A1 (fr) | 1991-06-13 | 1992-06-11 | Vaccin et methode de traitement des protozoaires flagelles parasites du sang |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1992022325A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029699A1 (fr) * | 1994-04-29 | 1995-11-09 | Curtis Powell | Vaccin, procede de determination diagnostique et procede de traitement des protozoaires hemoflagelles parasites |
| EP1048728A1 (fr) * | 1999-04-26 | 2000-11-02 | Stichting Dienst Landbouwkundig Onderzoek | Moyens et méthode pour la prévention et/ou le traitement des infections par le Trypanosome |
| WO2011058055A1 (fr) * | 2009-11-13 | 2011-05-19 | Universite Victor Segalen Bordeaux 2 | Applications therapeutiques et diagnostics contre les trypanosomoses |
-
1992
- 1992-06-11 WO PCT/US1992/004931 patent/WO1992022325A1/fr active Application Filing
Non-Patent Citations (4)
| Title |
|---|
| EXPERIMENTAL PARASITOLOGY, Volume 64, issued 1987, MCLAUGHLIN, "Trypanosoma rhodesiense: Antigenicity and Immunogenicity of Flagellar pocket Membrane Components", pages 1-11. * |
| INFECTION AND IMMUNITY, Volume 36, No. 1, issued April 1982, WELLS et al., "Immunization of Cattle with a Variant-Specific Antigen of Trypanosoma brucei: Influence of Different Adjuvants", pages 1-10. * |
| INFECTION AND IMMUNITY, Volume 43, issued January 1984, MCLAUGHLIN, "Evidence for Lipid-Protein Interactions in the Attachment of Antigens to a Low-Density Membrane Fraction isolated from Trypanosoma rhodesiense", pages 294-301. * |
| INFECTION AND IMMUNITY, Volume 56, issued January 1988, OLENICK et al., "A Flagellar pocket membrane fraction from Trypanosoma brucei Rhodensiense: Immunogold Localization and Nonvariant Immunoprotection", pages 92-98. * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995029699A1 (fr) * | 1994-04-29 | 1995-11-09 | Curtis Powell | Vaccin, procede de determination diagnostique et procede de traitement des protozoaires hemoflagelles parasites |
| US6027934A (en) * | 1994-04-29 | 2000-02-22 | Powell; Curtis | Vaccine for, diagnostic assay for and method of treating parasitic hemoflagellate protozoa |
| EP1048728A1 (fr) * | 1999-04-26 | 2000-11-02 | Stichting Dienst Landbouwkundig Onderzoek | Moyens et méthode pour la prévention et/ou le traitement des infections par le Trypanosome |
| WO2011058055A1 (fr) * | 2009-11-13 | 2011-05-19 | Universite Victor Segalen Bordeaux 2 | Applications therapeutiques et diagnostics contre les trypanosomoses |
| FR2952649A1 (fr) * | 2009-11-13 | 2011-05-20 | Univ Victor Segalen Bordeaux 2 | Applications therapeutiques et diagnostiques contre les trypanosomoses animales africaines |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mougneau et al. | Expression cloning of a protective Leishmania antigen | |
| Coler et al. | Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis | |
| US9511101B2 (en) | Compositions and methods for treatment of microbial infections | |
| Webb et al. | Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. | |
| CA2111189A1 (fr) | Traitement par voie orale de l'infection a helicobacter | |
| JPH10500958A (ja) | Ｈｅｌｉｃｏｂａｃｔｅｒの感染症の治療および予防 | |
| Mkunza et al. | Partial protection against natural trypanosomiasis after vaccination with a flagellar pocket antigen from Trypanosoma brucei rhodesiense | |
| US20150056243A1 (en) | Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure | |
| Mamaghani et al. | Toxoplasma gondii vaccine candidates: A concise review | |
| Ghaffarifar et al. | Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major | |
| Lu et al. | DNA vaccine ROP 29 from Toxoplasma gondii containing R848 enhances protective immunity in mice | |
| JP2534470B2 (ja) | 免疫グロブリンｇ含有製剤及びその製造方法 | |
| Suffia et al. | A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis | |
| Mukhopadhyay et al. | Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis | |
| Parody et al. | Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG+ Q mix protects Balb/c mice from infection | |
| WO1992022325A1 (fr) | Vaccin et methode de traitement des protozoaires flagelles parasites du sang | |
| AU610940B2 (en) | Vaccine against e.coli septicaemia in poultry | |
| TW200305433A (en) | Neospora vaccine | |
| JPH10508303A (ja) | Ｍｏｒａｘｅｌｌａの主要外層膜蛋白ＣＤ | |
| Hernandez-Flores et al. | Evaluation of the safety and adjuvant effect of a detoxified listeriolysin O mutant on the humoral response to dengue virus antigens | |
| CN110922454B (zh) | 绿脓杆菌毒素ExoS和ExoT的免疫用途及其制备方法 | |
| Szuster-Ciesielska et al. | Immunogenic Evaluation of Ribosomal P‐Protein Antigen P0, P1, and P2 and Pentameric Protein Complex P0‐(P1‐P2) 2 of Plasmodium falciparum in a Mouse Model | |
| EP2409987B1 (fr) | "Ribosomal P protein complex" de Plasmodium falciparum comme antigene d'un vaccin contre la malaria | |
| Joshua et al. | Could eggshell membrane be an adjuvant for recombinant Hepatitis B vaccine?: A preliminary investigation | |
| Yu et al. | Actin depolymerizing factor-based nanomaterials: A novel strategy to enhance E. mitis-specific immunity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR MW SD US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BE BF BJ CF CG CI CM DE FR GA GB GN ML MR NL SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |